1. IRF4 ablation in B cells abrogates allogeneic B cell responses and prevents chronic transplant rejection
- Author
-
Stephanie G. Yi, Dawei Zou, Yixuan Wang, Wenhao Chen, Xian Chang Li, A. Osama Gaber, Guohua Wang, and Nancy M. Gonzalez
- Subjects
Graft Rejection ,0301 basic medicine ,Pulmonary and Respiratory Medicine ,T cell ,Mice ,03 medical and health sciences ,0302 clinical medicine ,Plasma cell differentiation ,medicine ,Animals ,B cell ,Mice, Knockout ,B-Lymphocytes ,Mice, Inbred BALB C ,Transplantation ,biology ,business.industry ,Graft Survival ,Germinal center ,Skin Transplantation ,Germinal Center ,medicine.disease ,Transplant rejection ,Disease Models, Animal ,030104 developmental biology ,medicine.anatomical_structure ,Hemocyanins ,Interferon Regulatory Factors ,Cancer research ,biology.protein ,Heart Transplantation ,Surgery ,Antibody ,Cardiology and Cardiovascular Medicine ,business ,Haptens ,030215 immunology ,IRF4 - Abstract
BACKGOUND B cells contribute to chronic transplant rejection by producing donor-specific antibodies and promoting T cell response , but how these processes are regulated at the transcriptional level remains unclear. Herein, we investigate the role of transcription factor interferon regulatory factor 4 (IRF4) in controlling B cell response during chronic transplant rejection. METHODS We generated the Irf4gfp reporter mice to determine IRF4 expression in B cell lineage . We then used mice with B cell-specific IRF4 deletion to define the role of IRF4 in B cell response after NP-KLH immunization or allogeneic heart transplantation . In particular, graft survival and histology, as well as B and T cell responses, were evaluated after transplantation. RESULTS IRF4 is dynamically expressed at different stages of B cell development and is absent in germinal center (GC) B cells. However, IRF4 ablation in the B cell lineage primarily eliminates GC B cells in both naive and NP-KLH immunized mice. In the transplantation setting, IRF4 functions intrinsically in B cells and governs allogeneic B cell responses at multiple levels, including GC B cell generation, plasma cell differentiation, donor-specific antibody production , and support of T cell response. B cell-specific IRF4 deletion combined with transient CTLA4-Ig treatment abrogates acute and chronic cardiac allograft rejection in naive recipient mice but not in donor skin-sensitized recipients. CONCLUSIONS B cells require IRF4 to mediate chronic transplant rejection. IRF4 ablation in B cells abrogates allogeneic B cell responses and may also inhibit the ability of B cells to prime allogenic T cells . Targeting IRF4 in B cells represents a potential therapeutic strategy for eliminating chronic transplant rejection.
- Published
- 2021
- Full Text
- View/download PDF